Valley Wealth Managers Inc. Sells 5,314 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Valley Wealth Managers Inc. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 40,482 shares of the biopharmaceutical company’s stock after selling 5,314 shares during the quarter. Valley Wealth Managers Inc.’s holdings in Gilead Sciences were worth $3,739,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in GILD. nVerses Capital LLC bought a new position in Gilead Sciences during the 3rd quarter worth $25,000. HHM Wealth Advisors LLC increased its position in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares during the period. Valued Wealth Advisors LLC increased its position in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the period. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the fourth quarter worth $28,000. Finally, Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences in the fourth quarter worth $29,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $104.08 on Tuesday. The stock has a market capitalization of $129.71 billion, a price-to-earnings ratio of 1,156.44, a PEG ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $106.69. The stock’s 50 day moving average price is $93.87 and its two-hundred day moving average price is $87.70. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. On average, equities analysts predict that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.04%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Bank of America restated a “buy” rating and issued a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. The Goldman Sachs Group raised their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Finally, Royal Bank of Canada boosted their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $101.33.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 710,500 shares of company stock valued at $67,684,956 over the last ninety days. 0.16% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.